Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway

Fig. 1

NFAT5 was identified as a tumor suppressor in HCC. a Immunohistochemical analyses of HCC and para-tumor tissues showed that NFAT5 was downregulated in HCC tissues and expressed in the cytoplasm. Images at 100X and 400X magnification are displayed. b NFAT5 mRNA and protein was detected by RT-qPCR and western blot assay from 3 HCC patients. NFAT5 mRNA and protein was downregulated in HCC tumor tissue. **P < 0.01. (C) NFAT5 mRNA and protein expression in different HCC cell lines, compared to normal liver cell L02. All HCC cell produced less NFAT5 than L02. *P < 0.05. d Kaplan-Meier survival analysis for NFAT5. HCC patients with high NFAT5 expression have longer survival. e Left panel: FCM cell cycle assay showed NFAT5 knockdown accelerated S phase entry of HCC cells. Right panel: Statistical analysis of cell proportion in each cell cycle phase. *P < 0.05. f Left panel: NFAT5 knockdown suppressed the cell apoptosis, evaluated by FCM. Right panel: Statistical analysis showed NFAT5 knockdown significantly reduced apoptotic rate of HCC. *P < 0.05. g NFAT5 mRNA and protein expressed less in HepG2.2.15 than HepG2, detected by RT-qPCR and western blot. P = 0.002. h NFAT5 mRNA and protein expression was measured by RT-qPCR and Western-blotting in Huh 7 cells transfected with the plasmid pBlue-HBV at different times

Back to article page